[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 16 of about 16
1. Bozbuğa M, Turan Süslü H, Güler I, Bilgi B, Bayindir C: Removal of clival chordoma in an adolescent thorough combned pterional transsylvian and anterior temporal approach. Turk Neurosurg; 2007;17(1):55-9
Genetic Alliance. consumer health - Chordoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Removal of clival chordoma in an adolescent thorough combned pterional transsylvian and anterior temporal approach.
  • Extensive and aggressive surgical removal is treatment of choice for patients who have chordomas of the cranial base.
  • Well-developed microsurgical techniques, as well as good surgical judgment learned from experience are essential to avoid major morbidity.
  • The resected tumor had the typical histological and immunohistochemical characteristics of chordoma.
  • No radiation therapy or chemotherapy was administered.
  • [MeSH-major] Chordoma / surgery. Cranial Fossa, Posterior / surgery. Neurosurgical Procedures / methods. Skull Base Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17918681.001).
  • [ISSN] 1019-5149
  • [Journal-full-title] Turkish neurosurgery
  • [ISO-abbreviation] Turk Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


2. Casali PG, Stacchiotti S, Sangalli C, Olmi P, Gronchi A: Chordoma. Curr Opin Oncol; 2007 Jul;19(4):367-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chordoma.
  • PURPOSE OF REVIEW: To review developments in chordoma treatment.
  • Safe margins are often difficult to obtain due to the anatomical sites of chordoma: sacrum, skull base and spine.
  • Tumors in these sites are problematic for radiation therapy as well, and this adds to the need for high doses.
  • New photon beam techniques, e.g. intensity modulated radiation therapy and stereotactic procedures, have recently been evaluated.
  • While chemotherapy is poorly active, recent interest has focused on molecular-targeted agents.
  • Imatinib was shown to be active, providing mainly nondimensional tissue responses in a significant proportion of patients, which may improve symptoms and progression-free interval.
  • Epidermal growth factor receptor targeting, anti-angiogenics, and the combination of targeted agents with chemotherapy and radiation therapy are also under scrutiny.
  • SUMMARY: Two major issues about local treatment remain unresolved: when to complement surgery with radiation therapy, and how best to deliver high doses of radiation therapy to the tumor tissue.
  • Regarding systemic treatment, there is ongoing research into how to exploit molecular-targeted therapies.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Chordoma / drug therapy. Chordoma / radiotherapy. Piperazines / therapeutic use. Protein Kinase Inhibitors / therapeutic use. Pyrimidines / therapeutic use. Skull Base Neoplasms / drug therapy. Skull Base Neoplasms / radiotherapy. Spinal Neoplasms / drug therapy. Spinal Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Chordoma.
  • Genetics Home Reference. consumer health - chordoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17545801.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  • [Number-of-references] 45
  •  go-up   go-down


3. Stacchiotti S, Marrari A, Tamborini E, Palassini E, Virdis E, Messina A, Crippa F, Morosi C, Gronchi A, Pilotti S, Casali PG: Response to imatinib plus sirolimus in advanced chordoma. Ann Oncol; 2009 Nov;20(11):1886-94
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to imatinib plus sirolimus in advanced chordoma.
  • BACKGROUND: Imatinib (IM) is active in advanced chordoma.
  • The evidence of upstream and/or downstream mammalian target of rapamycin (mTOR) pathway activation prompted us to combine an mTOR inhibitor, sirolimus, to IM in IM-resistant advanced chordoma.
  • PATIENTS AND METHODS: Since July 2007, 10 progressive advanced chordoma patients with secondary resistance to IM, and biochemical and/or immunohistochemical evidence of upstream and/or downstream mTOR effector activation, started IM (400 mg/day) plus sirolimus (2 mg/day) on a named basis.
  • RESULTS: The mean treatment duration was 9 months.
  • Seven patients had a positron emission tomography response.
  • Post-treatment biopsy in one responsive patient confirmed S6 switch off.

  • Genetic Alliance. consumer health - Chordoma.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19570961.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.11.1 / Oncogene Protein v-akt; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


Advertisement
4. Orzan F, Terreni MR, Longoni M, Boari N, Mortini P, Doglioni C, Riva P: Expression study of the target receptor tyrosine kinase of Imatinib mesylate in skull base chordomas. Oncol Rep; 2007 Jul;18(1):249-52
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression study of the target receptor tyrosine kinase of Imatinib mesylate in skull base chordomas.
  • Up to now, the most suitable therapeutic approach is based on a combination of surgical excision and radiotherapy.
  • Chemotherapy in not applied due to its reported low efficacy.
  • We analyzed 14 chordoma samples for the expression of the Imatinib mesylate targets by means of RT-PCR and immunohistochemistry and found that PDGFR alpha and PDGFR beta are in some cases expressed in neoplastic cells, while the stromal counterpart of the same tumor shows the above receptors.
  • Our study provides new insights into the specific localization of Imatinib mesylate targets in skull base chordomas that could be taken into account for the setting up of a pharmacological treatment for this tumor.
  • [MeSH-major] Chordoma / metabolism. Piperazines / therapeutic use. Proto-Oncogene Proteins c-kit / metabolism. Pyrimidines / therapeutic use. Receptor, Platelet-Derived Growth Factor alpha / metabolism. Receptor, Platelet-Derived Growth Factor beta / metabolism. Skull Base Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Benzamides. Female. Humans. Imatinib Mesylate. Immunoenzyme Techniques. Male. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Receptor Protein-Tyrosine Kinases / antagonists & inhibitors. Reverse Transcriptase Polymerase Chain Reaction. Stromal Cells / metabolism. Stromal Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17549375.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  •  go-up   go-down


5. Ostroumov E, Hunter CJ: The role of extracellular factors in human metastatic chordoma cell growth in vitro. Spine (Phila Pa 1976); 2007 Dec 15;32(26):2957-64
Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of extracellular factors in human metastatic chordoma cell growth in vitro.
  • STUDY DESIGN: Human metastatic chordoma cells were isolated, and initial in vitro characterization was performed.
  • OBJECTIVE: The extracellular microenvironment directly affects metastatic chordoma cell phenotype in vitro.
  • SUMMARY OF BACKGROUND DATA: Chordomas are primary bone tumors that usually occur in the spine or skull.
  • Chordomas arise from embryonic notochordal remnants along the axial skeleton, most commonly the sacrum, followed by the base of the skull and the mobile spine.
  • Due to a high degree of resistance to radiation and chemotherapy, chordomas eventually cause death by direct growth or by metastasizing to other organs.
  • RESULTS: In this study, we present a new chordoma cell line established from metastatic tissue and novel data characterizing some aspects of chordoma cell phenotype in different conditions in vitro.
  • Chordoma biologic markers were expressed in the new cell line.
  • Chordoma's preferred extracellular microenvironment in vitro was rather alkaline, with an optimum at pH 8.5, and apoptotic changes were induced at acidic pH.
  • We found that bovine serum albumin was accumulated by chordoma cells from the incubation media, and this accumulation depended on extracellular pH, with the highest accumulation at alkaline pH.
  • [MeSH-major] Chordoma / pathology. Chordoma / secondary. Extracellular Fluid / physiology

  • Genetic Alliance. consumer health - Chordoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18091487.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


6. Schönegger K, Gelpi E, Prayer D, Dieckmann K, Matula C, Hassler M, Hainfellner JA, Marosi C: Recurrent and metastatic clivus chordoma: systemic palliative therapy retards disease progression. Anticancer Drugs; 2005 Nov;16(10):1139-43
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent and metastatic clivus chordoma: systemic palliative therapy retards disease progression.
  • We report on a male patient with progressive and metastatic clivus chordoma treated over a period of 9 years by a multidisciplinary approach.
  • Within the first 4 years, the patient underwent surgery four times.
  • Thereafter, he received radiotherapy and subsequent chemotherapy.
  • Stabilization of disease was achieved repeatedly for variable periods under local radiotherapy, systemic chemotherapy, immunomodulatory and anti-angiogenic therapy with isotretinoin and interferon-alpha, followed by thalidomide.
  • Our observations show that multimodal therapy including a systemic palliative approach is associated with long quiescent intervals in recurrent chordoma and with regression of its metastases.
  • Use of substances with high efficacy on tumor tissue and low toxicity, allowing long-term administration, seems promising in similar situations.
  • [MeSH-major] Chordoma / secondary. Chordoma / therapy. Cranial Fossa, Posterior. Neoplasm Recurrence, Local / therapy. Palliative Care. Skull Base Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Disease Progression. Humans. Karnofsky Performance Status. Male. Middle Aged. Recurrence. Treatment Outcome

  • Genetic Alliance. consumer health - Chordoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16222158.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


7. Tsai EC, Santoreneos S, Rutka JT: Tumors of the skull base in children: review of tumor types and management strategies. Neurosurg Focus; 2002 May 15;12(5):e1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumors of the skull base in children: review of tumor types and management strategies.
  • Although many treatment strategies for skull base tumors in adults have been reported, relatively little has been reported regarding such therapies in the pediatric population.
  • Skull base tumors in children present a therapeutic challenge because of their unique pathological composition, the constraints of the maturing skull and brain, and the small size of the patients.
  • In this review, the authors examine the pediatric skull base lesions that occur in the anterior, middle, and posterior cranial base, focusing on unique pediatric tumors such as encepahalocele, fibrous dysplasia, esthesioneuroblastoma, craniopharyngioma, juvenile nasopharyngeal angiofibroma, cholesteatoma, chordoma, chondrosarcoma, and Ewing sarcoma.
  • They review management strategies that include radio- and chemotherapy, as well as surgical approaches with emphasis on the modifications and complications associated with the procedures as they apply in children.
  • Evidence for the advantages and limitations of radiotherapy, chemotherapy, and surgery as it pertains to the pediatric population will be examined.
  • With a working knowledge of skull base anatomy and special considerations of the developing craniofacial skeleton, neurosurgeons can treat skull base lesions in children with acceptable morbidity and mortality rates.
  • Outcomes in this population may be better than those in adults, in part because of the benign histopathology that frequently affects the pediatric skull base, as well as the plasticity of the maturing nervous system.
  • [MeSH-major] Skull Base Neoplasms
  • [MeSH-minor] Adolescent. Angiofibroma / radiotherapy. Angiofibroma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Cholesteatoma / surgery. Chondrosarcoma / drug therapy. Chondrosarcoma / radiotherapy. Chondrosarcoma / surgery. Chordoma / surgery. Combined Modality Therapy. Craniopharyngioma / epidemiology. Craniopharyngioma / radiotherapy. Craniopharyngioma / surgery. Encephalocele / epidemiology. Encephalocele / surgery. Esthesioneuroblastoma, Olfactory / drug therapy. Esthesioneuroblastoma, Olfactory / mortality. Esthesioneuroblastoma, Olfactory / surgery. Female. Fibrous Dysplasia of Bone / pathology. Fibrous Dysplasia of Bone / surgery. Humans. Infant. Male. Neurosurgical Procedures / methods. Nose Neoplasms / radiotherapy. Nose Neoplasms / surgery. Pituitary Neoplasms / epidemiology. Pituitary Neoplasms / radiotherapy. Pituitary Neoplasms / surgery. Sarcoma, Ewing / therapy. Skull / pathology. Skull / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16119897.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 143
  •  go-up   go-down


8. Hof H, Welzel T, Debus J: Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma. Onkologie; 2006 Dec;29(12):572-4
Hazardous Substances Data Bank. CETUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma.
  • BACKGROUND: Chordomas are rare tumors of the skull base and the spine.
  • Treatment is difficult since conventional radiotherapy or chemotherapy have only limited effects.
  • PATIENT AND METHODS: A patient with a sacral chordoma and pulmonary metastases received initial surgery and radiotherapy for a local recurrence.
  • As tumor biopsies revealed the expression of the EGF receptor an individual treatment approach with a combination of cetuximab and gefitinib was performed.
  • RESULTS: Under the treatment with cetuximab/gefitinib the local recurrence and the pulmonary metastases showed a partial response over the follow-up period of 9 months.
  • To date no treatment failure was observed.
  • CONCLUSIONS: The inhibition of the EGF pathway seems to be an effective measure in the treatment of a chordoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Chordoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Sacrum. Spinal Neoplasms / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Cetuximab. Humans. Male. Middle Aged. Quinazolines / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Chordoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17202828.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Quinazolines; PQX0D8J21J / Cetuximab; S65743JHBS / gefitinib
  •  go-up   go-down


9. Rutz HP, Weber DC, Goitein G, Ares C, Bolsi A, Lomax AJ, Pedroni E, Coray A, Hug EB, Timmermann B: Postoperative spot-scanning proton radiation therapy for chordoma and chondrosarcoma in children and adolescents: initial experience at paul scherrer institute. Int J Radiat Oncol Biol Phys; 2008 May 1;71(1):220-5
Genetic Alliance. consumer health - Chordoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative spot-scanning proton radiation therapy for chordoma and chondrosarcoma in children and adolescents: initial experience at paul scherrer institute.
  • PURPOSE: To evaluate postoperative spot-scanning proton radiation therapy (PT) and intensity-modulated PT (IMPT) for chordoma and chondrosarcoma in pediatric patients.
  • Tumor sites were in the brain (one case), skull base (five cases), cervical (three cases), and lumbar spine (one case).
  • Total dose was 74.0 cobalt Gray equivalents (CGE) for chordoma, and 63.2-68.0 CGE for chondrosarcoma (median, 66.0), depending on histopathological grading and whether the patient had concurrent chemotherapy.
  • RESULTS: Median follow-up time was 36 months (range, 8-77 months).
  • Radiation treatment was well tolerated.
  • CONCLUSIONS: Postoperative spot-scanning PT, delivered in combination with and without IMPT, for chordoma and chondrosarcoma in children and adolescents was tolerated without unacceptable adverse event and initial outcome is perfectly satisfactory in this small cohort.
  • Longer follow-up time and larger cohort are needed to more fully assess tumor control, adverse events, as well as functional and cosmetic outcome.
  • [MeSH-major] Chondrosarcoma / radiotherapy. Chordoma / radiotherapy. Protons / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Child. Female. Head and Neck Neoplasms / radiotherapy. Head and Neck Neoplasms / surgery. Humans. Male. Neoplasm Recurrence, Local / radiotherapy. Postoperative Period. Radiation Injuries / complications. Radiotherapy, Intensity-Modulated. Skull Base Neoplasms / radiotherapy. Skull Base Neoplasms / surgery. Spinal Neoplasms / radiotherapy. Spinal Neoplasms / surgery

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18068310.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


10. Rhomberg W, Böhler FK, Novak H, Dertinger S, Breitfellner G: A small prospective study of chordomas treated with radiotherapy and razoxane. Strahlenther Onkol; 2003 Apr;179(4):249-53
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The rationale for this procedure were improved results previously seen in soft tissue and chondrosarcomas with this combination.
  • PATIENTS AND METHODS: Between 1988 and 1996, five patients with histologically confirmed chordomas of the skull base or the spine (three females, two males) were irradiated with 6- and 25-MeV photons under razoxane medication, one patient was treated with a telecobalt unit.
  • Single doses of 180-200 cGy were given five times a week.
  • The median total tumor dose was 63 Gy (range 54-67 Gy).
  • The drug was started 3-5 days before the first irradiation, and continued until the end of radiotherapy.
  • RESULTS: After a potential median follow-up time of 10 years, three of the five patients are alive and show neither symptoms nor signs of recurrence in CT or MR images.
  • One patient with persistent sacral chordoma died after 8 years from cardiac insufficiency, and another patient died after 6.5 years from a bleeding complication following surgery for recurrence.
  • Acute side effects included mucosal reactions, two of five patients developed a leukopenia WHO grade 3 due to razoxane.
  • The cases are unselected, and the follow-up time is of considerable duration.
  • The treatment can easily be performed at any institution and is tolerated fairly well.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Chordoma / drug therapy. Chordoma / radiotherapy. Immunosuppressive Agents / therapeutic use. Lumbar Vertebrae. Radiation-Sensitizing Agents / therapeutic use. Razoxane / therapeutic use. Sacrum. Skull Base Neoplasms / drug therapy. Skull Base Neoplasms / radiotherapy. Spinal Neoplasms / drug therapy. Spinal Neoplasms / radiotherapy. Thoracic Vertebrae
  • [MeSH-minor] Adolescent. Adult. Aged. Cobalt Radioisotopes / therapeutic use. Combined Modality Therapy. Dose Fractionation. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Photons / therapeutic use. Prospective Studies. Radioisotope Teletherapy. Radiotherapy Dosage. Time Factors. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12707714.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cobalt Radioisotopes; 0 / Immunosuppressive Agents; 0 / Radiation-Sensitizing Agents; 5AR83PR647 / Razoxane
  •  go-up   go-down


11. Huang Q, Wu H, Wang Z, Zhang Z, Jia H: [Diagnosis and treatment of lateral skull base tumors in pediatric]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2008 Aug;22(16):734-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of lateral skull base tumors in pediatric].
  • OBJECTIVE: To explore the diagnosis and treatment of lateral skull base tumors in children.
  • METHOD: The clinical data of 8 patients with lateral skull base tumors were reviewed in a retrospective study.
  • One had schwannoma of the trigeminal nerve, one had malignant melanoma, one had fibroma in temporal bone, one had chordoma, two had rhabdomyosarcoma, two had esthesioneuroblastoma.
  • Of 8 patients, one case was treated with chemotherapy.
  • Four patients had pre-and postoperative chemotherapy.
  • Three patients received postoperative chemotherapy.
  • One patient of chordoma died 5 months after surgery, the other 7 patients were alive at the time of analysis.
  • One patient developed hoarseness.
  • Two patients developed swallowing obstruction and healed 3-4 months after surgery.
  • CONCLUSION: Tumors in lateral skull base in children were rare, of which malignant tumors were more common compared to benign lesions.
  • Surgery is the first choice of the treatment for lateral skull base tumors.
  • Radiation therapy and chemotherapy could be used for malignant tumors preoperatively and postoperatively.
  • [MeSH-major] Skull Base Neoplasms / diagnosis. Skull Base Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18975775.001).
  • [ISSN] 1001-1781
  • [Journal-full-title] Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery
  • [ISO-abbreviation] Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


12. Muro K, Das S, Raizer JJ: Chordomas of the craniospinal axis: multimodality surgical, radiation and medical management strategies. Expert Rev Neurother; 2007 Oct;7(10):1295-312
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chordomas are neoplasms of the primitive notochord remnants and are characterized by slow growth kinetics, locally aggressive behavior and resistance to conventional therapeutic options.
  • They are found primarily in the skull base or the sacral region, although they can occur anywhere in the craniospinal axis.
  • Chemotherapy plays a limited role and currently remains an option at tumor recurrence, although increasing knowledge of the molecular biology of chordomas may lead to targeted therapeutic strategies.
  • In this review, the current multimodality treatment strategy for chordomas will be discussed and future directions will be highlighted.
  • [MeSH-major] Chordoma / radiotherapy. Chordoma / surgery
  • [MeSH-minor] Animals. Combined Modality Therapy. Humans. Skull Neoplasms / diagnosis. Skull Neoplasms / drug therapy. Skull Neoplasms / radiotherapy. Skull Neoplasms / surgery. Spinal Neoplasms / diagnosis. Spinal Neoplasms / drug therapy. Spinal Neoplasms / radiotherapy. Spinal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17939768.001).
  • [ISSN] 1744-8360
  • [Journal-full-title] Expert review of neurotherapeutics
  • [ISO-abbreviation] Expert Rev Neurother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 125
  •  go-up   go-down


13. Pallini R, Sabatino G, Doglietto F, Lauretti L, Fernandez E, Maira G: Clivus metastases: report of seven patients and literature review. Acta Neurochir (Wien); 2009 Apr;151(4):291-6; discussion 296

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Tumours of the clivus are rare and metastases involving this area have been previously described only as single case reports or included in series with other skull base tumours.
  • This figure represents 0.18% and 0.42% respectively of intracranial and skull base tumours which were treated in our Institution in the study period.
  • In spite of radiotherapy and chemotherapy, the mean survival was 12 months.
  • CONCLUSION: Though exceedingly rare, metastases involving the clivus should be considered in the differential diagnosis with clivus chordoma.
  • The trans-sphenoidal approach is the ideal procedure to establish a histopathological diagnosis.
  • [MeSH-major] Carcinoma / secondary. Cranial Fossa, Posterior / pathology. Skull Base Neoplasms / secondary
  • [MeSH-minor] Abducens Nerve Diseases / etiology. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Liver Neoplasms / pathology. Lung Neoplasms / pathology. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Metastasis. Prognosis. Prostatic Neoplasms / pathology. Skin Neoplasms / pathology. Survival Rate. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19259614.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Austria
  • [Number-of-references] 30
  •  go-up   go-down


14. Kilgore S, Prayson RA: Apoptotic and proliferative markers in chordomas: a study of 26 tumors. Ann Diagn Pathol; 2002 Aug;6(4):222-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Five tumors locally recurred; two patients developed metastatic disease.
  • Thirteen patients received adjuvant chemotherapy and/or radiation therapy.
  • [MeSH-major] Apoptosis. Biomarkers, Tumor / analysis. Chordoma / pathology
  • [MeSH-minor] Adult. Aged. Apoptosis Regulatory Proteins. Carrier Proteins / analysis. Cranial Fossa, Posterior / pathology. Cyclin D1 / analysis. Female. Humans. Immunoenzyme Techniques. Ki-67 Antigen / analysis. Lumbosacral Region / pathology. Male. Middle Aged. Retrospective Studies. Skull Base Neoplasms / mortality. Skull Base Neoplasms / pathology. Skull Base Neoplasms / therapy. Survival Analysis. Tumor Suppressor Protein p53 / analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002, Elsevier Science (USA). All rights reserved.
  • (PMID = 12170453.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Ki-67 Antigen; 0 / TP53BP2 protein, human; 0 / Tumor Suppressor Protein p53; 136601-57-5 / Cyclin D1
  •  go-up   go-down


15. Güneş M, Günaldi O, Tuğcu B, Tanriverdi O, Güler AK, Cöllüoğlu B: Intracranial chondrosarcoma: a case report and review of the literature. Minim Invasive Neurosurg; 2009 Oct;52(5-6):238-41
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for intracranial chondrosarcoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Chondrosarcoma is a rare malignant tumor originating from cartilagenous tissue.
  • Skull radiography revealed a radioopaque lesion in the right parieto-occipital region.
  • Cranial computed tomography and magnetic resonance imaging showed a mass lesion including calcification areas and homogenous contrast enhancement in the right parieto-occipital region.
  • A classical type chondrosarcoma was confirmed histopathologically.
  • Most of them are located at the skull base.
  • Meningiomas, solitary fibrous tumor, chordoma, hemangiopericytoma, metastasis and vascular malformations should be considered as differential diagnoses.
  • Radical surgical removal of the tumor is the preferred management procedure.
  • Chemotherapy and radiotherapy may by added as adjuvant therapy.
  • [MeSH-minor] Adult. Humans. Magnetic Resonance Imaging. Male. Microsurgery. Neurosurgical Procedures. Prognosis. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20077365.001).
  • [ISSN] 1439-2291
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 26
  •  go-up   go-down


16. Rawlins JM, Batchelor AG, Liddington MI, Towns G: Tumor excision and reconstruction of the upper cervical spine: a multidisciplinary approach. Plast Reconstr Surg; 2004 Nov;114(6):1534-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Axis, Cervical Vertebra / surgery. Cervical Atlas / surgery. Chondrosarcoma / surgery. Chordoma / surgery. Cranial Fossa, Posterior / surgery. Osteosarcoma / surgery. Patient Care Team. Skull Base Neoplasms / surgery. Spinal Neoplasms / surgery
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Transplantation. Chemotherapy, Adjuvant. Combined Modality Therapy. Etoposide / administration & dosage. Fatal Outcome. Female. Femoral Neoplasms / drug therapy. Femoral Neoplasms / pathology. Femoral Neoplasms / radiotherapy. Femoral Neoplasms / surgery. Humans. Ifosfamide / administration & dosage. Interdisciplinary Communication. Internal Fixators. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Male. Methotrexate / administration & dosage. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local. Palliative Care. Protons / therapeutic use. Remission Induction. Spinal Fusion. Surgical Flaps

  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15509945.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons; 6PLQ3CP4P3 / Etoposide; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down






Advertisement